S Romagnani1. 1. Department of Internal Medicine, University of Florence, Firenze, Italy.
Abstract
LEARNING OBJECTIVE: To understand the current status of knowledge in the basic field of polarized specific immune responses mediated by CD4+ T helper (Th) lymphocytes, based on their profile of cytokine production (type 1 or Th1 and type 2 or Th2). DATA SOURCES: Relevant articles and publications from the medical literature, especially review articles dealing with properties, mechanisms of polarization, transcription regulatory factors, and role in different human pathophysiological conditions of Th1 and Th2 cells. CONCLUSIONS: Th1 cells, which produce interferon (IFN)-gamma, interleukin (IL)-2 and tumor necrosis factor (TNF)-beta, evoke cell-mediated immunity and phagocyte-dependent inflammation. Th2 cells, which produce IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13, evoke strong antibody responses (including those of the IgE class) and eosinophil accumulation, but inhibit several functions of phagocytic cells (phagocyte-independent inflammation). Both environmental and genetic factors act in concert to determine the Th1 or Th2 polarization. Further, Th1-dominated responses are involved in the pathogenesis of organ-specific autoimmune disorders, Crohn's disease, sarcoidosis, acute kidney allograft rejection, and some unexplained recurrent abortions. In contrast, allergen-specific Th2 responses are responsible for atopic disorders in genetically susceptible individuals. Further, Th2-dominated responses play a pathogenic role in both progressive systemic sclerosis and cryptogenic fibrosing alveolitis, and favor a more rapid evolution of HIV infection towards the full-blown disease. Finally, the Th1/Th2 paradigm can provide the basis for the development of new types of vaccines against infectious agents and of novel strategies for the therapy of allergic and autoimmune disorders.
LEARNING OBJECTIVE: To understand the current status of knowledge in the basic field of polarized specific immune responses mediated by CD4+ T helper (Th) lymphocytes, based on their profile of cytokine production (type 1 or Th1 and type 2 or Th2). DATA SOURCES: Relevant articles and publications from the medical literature, especially review articles dealing with properties, mechanisms of polarization, transcription regulatory factors, and role in different human pathophysiological conditions of Th1 and Th2 cells. CONCLUSIONS:Th1 cells, which produce interferon (IFN)-gamma, interleukin (IL)-2 and tumor necrosis factor (TNF)-beta, evoke cell-mediated immunity and phagocyte-dependent inflammation. Th2 cells, which produce IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13, evoke strong antibody responses (including those of the IgE class) and eosinophil accumulation, but inhibit several functions of phagocytic cells (phagocyte-independent inflammation). Both environmental and genetic factors act in concert to determine the Th1 or Th2 polarization. Further, Th1-dominated responses are involved in the pathogenesis of organ-specific autoimmune disorders, Crohn's disease, sarcoidosis, acute kidney allograft rejection, and some unexplained recurrent abortions. In contrast, allergen-specific Th2 responses are responsible for atopic disorders in genetically susceptible individuals. Further, Th2-dominated responses play a pathogenic role in both progressive systemic sclerosis and cryptogenic fibrosing alveolitis, and favor a more rapid evolution of HIV infection towards the full-blown disease. Finally, the Th1/Th2 paradigm can provide the basis for the development of new types of vaccines against infectious agents and of novel strategies for the therapy of allergic and autoimmune disorders.
Authors: Marie McGee Hargrove; John K McGee; Eugene A Gibbs-Flournoy; Charles E Wood; Yong Ho Kim; M Ian Gilmour; Stephen H Gavett Journal: Inhal Toxicol Date: 2018-12-05 Impact factor: 2.724
Authors: Jessica L Reynolds; Wing Cheung Law; Supriya D Mahajan; Ravikumar Aalinkeel; Bindukumar Nair; Donald E Sykes; Ken-Tye Yong; Rui Hui; Paras N Prasad; Stanley A Schwartz Journal: J Neuroimmune Pharmacol Date: 2012-06-12 Impact factor: 4.147
Authors: Nrupen A Bhavsar; Jay H Bream; Alan K Meeker; Charles G Drake; Sarah B Peskoe; Djeneba Dabitao; Angelo M De Marzo; William B Isaacs; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08-22 Impact factor: 4.254
Authors: Joseph P Erinjeri; Contessa T Thomas; Alaiksandra Samoilia; Martin Fleisher; Mithat Gonen; Constantinos T Sofocleous; Raymond H Thornton; Robert H Siegelbaum; Anne M Covey; Lynn A Brody; William Alago; Majid Maybody; Karen T Brown; George I Getrajdman; Stephen B Solomon Journal: J Vasc Interv Radiol Date: 2013-04-10 Impact factor: 3.464